CREON

Main information

  • Trade name:
  • CREON Capsule 25000 Milligram
  • Dosage:
  • 25000 Milligram
  • Pharmaceutical form:
  • Capsule
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CREON Capsule 25000 Milligram
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PPA1562/008/002
  • Authorization date:
  • 14-08-2009
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

Creon25000Gastro-ResistantCapsules

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachcapsulecontains300mgPancreatinequivalentto:

Lipase25,000Ph.Eur.units

Amylase18,000Ph.Eur.units

Protease1,000Ph.Eur.Units

Forafulllistofexcipients,seesection6.1

3PHARMACEUTICALFORM

Gastro-resistantcapsules,hard.

ProductimportedfromtheUK

Capsuleswithorangecapsandcolourlesstransparentbodieswithbrownishgranules

(minimicrospheres).

4CLINICALPARTICULARS

4.1TherapeuticIndications

Forthetreatmentofpancreaticexocrinedeficiency.

4.2Posologyandmethodofadministration

Adults(includingtheelderly)andchildren:

Initiallyonecapsulewithmeals.Doseincreases,ifrequired,shouldbeaddedslowly,withcarefulmonitoringof

responseandsymptomatology.

Thedailydoseofpancreaticenzymesformostpatientsshouldremainbelow2500unitsoflipaseperkilogrampermeal

(10,000unitsperkilogramperday),andthathigherdosesshouldbeusedwithcautionandonlyifquantitative

measuresdemonstratesubstantiallyimprovedabsorptionwithsuchtreatment.Thisparticularlyappliestoyoung

children.

ItisimportanttoensureadequatehydrationofpatientsatalltimeswhilstdosingCreon25000.

Thecapsulescanbeswallowedwhole,orforeaseofadministrationtheymaybeopenedandthegranulestakenwith

fluidorsoftfood.Ifthegranulesaremixedwithfood,itisimportantthattheyaretakenimmediately,otherwise

dissolutionoftheentericcoatingmayresult.Inordertoprotecttheentericcoating,itisimportantthatthegranulesare

notcrushedorchewed.

Colonicdamagehasbeenreportedinpatientswithcysticfibrosistakinghighdosesofpancreaticenzymesupplements

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/12/2011 CRN 2108581 page number: 1

4.3Contraindications

Patientswithknownhypersensitivitytoporcineproteins.

4.4Specialwarningsandprecautionsforuse

Theproductisofporcineorigin.

Oralmedicationsshouldnotbeadministeredduringtheearlystagesofacutepancreatitis.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.6Fertility,pregnancyandlactation

TherearenoadequatedatafromtheuseofCreoninpregnantwomen.Animalstudiesareinsufficientwithrespectto

effectsonpregnancyandembryonal/foetaldevelopment,parturition/andpostnataldevelopment.Thepotentialriskfor

humansisunknown.Creonshouldnotbeusedduringpregnancyorlactationunlessclearlynecessarybutifrequired

shouldbeusedindosesprovidingadequatenutritionalstatus(seewarningsabouthighdosesections4.2and4.8.).

4.7Effectsonabilitytodriveandusemachines

Noneexpected.

4.8Undesirableeffects

1.Rarely,casesofhyper-uricosuriaandhyper-uricaemiahavebeenreportedwithveryhighdosesofpancreatin.

2.Meconiumileustypeobstructivesymptomsandcasesofcolonicstricture

resultinginbowelre-section,havebeenseenwithhighdosesofpancreaticenzymesupplements.Similarproblems

havenotoccurredtodatewiththisproduct.However,unusualabdominalsymptomsorchangesinabdominal

symptomsshouldbereviewedtoexcludethepossibilityofcolonicdamage.

3.ThefollowingunwantedeffectshavebeenreportedwithCreon:diarrhoea,constipation,stomachpains,feelingsick,

andskinreactions(rash,itching).

4.9Overdose

Mostcasesrespondtosupportivemeasuresincludingstoppingenzymetherapy,ensuringadequaterehydration.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Replacementtherapyinpancreaticenzymedeficiencystates.Theenzymeshavehydrolyticactivityonfat,

carbohydratesandproteins.

5.2Pharmacokineticproperties

Pharmacokineticdataarenotavailableastheenzymesactlocallyinthegastro-intestinaltract.Afterexertingtheir

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/12/2011 CRN 2108581 page number: 2

5.3Preclinicalsafetydata

Nonestated.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Granules

Macrogol4000

Hypromellosephthalate

Dimeticone

Triethylcitrate

Cetylalcohol

Capsules

Gelatin

Ironoxides(E172)

Titaniumdioxide(E171)

Sodiumlaurilsulfate

6.2Incompatibilities

Notapplicable

6.3Shelflife

Theshelflifeexpirydateforthisproductshallbethedateshownonthecontainerandouterpackageoftheproducton

themarketinthecountryoforigin.

6.4Specialprecautionsforstorage

Donotstoreabove25°Candkeepintheoriginalcontainer.

Keepthecontainertightlyclosed.

6.5Natureandcontentsofcontainer

HDPEcontainerwithpolypropylenecap.Containershold100capsules.

6.6Specialprecautionsfordisposalandotherhandling

Nospecialrequirements

7PARALLELPRODUCTAUTHORISATIONHOLDER

LTTPharmaLimited

Unit18

OxleasowRoad

EastMoonMoat

Redditch

Worcestershire

B980RE

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/12/2011 CRN 2108581 page number: 3

8PARALLELPRODUCTAUTHORISATIONNUMBER

PPA1562/8/2

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:14thAugust2009

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 20/12/2011 CRN 2108581 page number: 4